Karyopharm Therapeutics (KPTI) Non-Current Deffered Revenue (2014 - 2020)

Karyopharm Therapeutics (KPTI) has 7 years of Non-Current Deffered Revenue data on file, last reported at $2.2 million in Q1 2020.

• Quarterly Non-Current Deffered Revenue fell 32.45% year-over-year to $2.2 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $2.2 million (down 32.45% YoY) and the FY2019 annual result came in at $2.2 million, down 44.11% from the prior year.
• Non-Current Deffered Revenue was little changed at $2.2 million in Q1 2020, from $2.2 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $4.5 million in Q2 2018 to a low of $1.4 million in Q4 2017.
• A 5-year average of $2.5 million and a median of $1.9 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue jumped 214.5% — and 2019, when it sank 44.11%.
• Tracing KPTI's Non-Current Deffered Revenue over 5 years: stood at $1.7 million in 2016, then retreated by 18.19% to $1.4 million in 2017, then soared by 187.75% to $3.9 million in 2018, then slumped by 44.11% to $2.2 million in 2019, then changed by 0.0% to $2.2 million in 2020.
• The last three Non-Current Deffered Revenue figures came in at $2.2 million (Q1 2020), $2.2 million (Q4 2019), and $3.5 million (Q3 2019), per Business Quant data.